KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other Non-Current Assets (2016 - 2025)

Vertex Pharmaceuticals has reported Other Non-Current Assets over the past 17 years, most recently at $1.2 billion for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $1.2 billion for Q4 2025, up 23.75% from a year ago — trailing twelve months through Dec 2025 was $1.2 billion (up 23.75% YoY), and the annual figure for FY2025 was $1.2 billion, up 23.75%.
  • Other Non-Current Assets for Q4 2025 was $1.2 billion at Vertex Pharmaceuticals, up from $1.1 billion in the prior quarter.
  • Over the last five years, Other Non-Current Assets for VRTX hit a ceiling of $1.2 billion in Q4 2025 and a floor of $49.3 million in Q1 2021.
  • Median Other Non-Current Assets over the past 5 years was $459.0 million (2023), compared with a mean of $576.4 million.
  • Biggest five-year swings in Other Non-Current Assets: plummeted 79.72% in 2021 and later surged 286.18% in 2023.
  • Vertex Pharmaceuticals' Other Non-Current Assets stood at $110.8 million in 2021, then soared by 269.68% to $409.6 million in 2022, then soared by 118.58% to $895.3 million in 2023, then increased by 11.62% to $999.3 million in 2024, then grew by 23.75% to $1.2 billion in 2025.
  • The last three reported values for Other Non-Current Assets were $1.2 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.1 billion (Q2 2025) per Business Quant data.